Bill
Bill > H1527
FL H1527
FL H1527Prohibitions Against Discriminatory Practices Relating to 340B Entities and 340B Drugs
summary
Introduced
02/28/2025
02/28/2025
In Committee
03/05/2025
03/05/2025
Crossed Over
Passed
Dead
06/16/2025
06/16/2025
Introduced Session
2025 Regular Session
Bill Summary
An act relating to prohibitions against discriminatory practices relating to 340B entities and 340B drugs; creating s. 499.0263, F.S.; providing definitions; prohibiting drug manufacturers from engaging in certain acts against the acquisitions of 340B drugs by and the delivery of such drugs to specified pharmacies; providing an exception; prohibiting drug manufacturers from interfering with pharmacies' rights to contract with 340B entities; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; creating s. 626.8829, F.S.; defining terms; prohibiting certain acts by health insurance issuers, pharmacy benefit managers, or other third-party payors, or their agents, relating to reimbursement to a 340B entity for 340B drugs; providing applicability; prohibiting certain acts by manufacturers relating to interference with the acquisition of a 340B drug; prohibiting a manufacturer's interference with a pharmacy's right to contract with a 340B entity; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; creating ss. 627.64743, 627.65733, and 641.31543, F.S.; defining terms; prohibiting individual health insurers, group, blanket, and franchise health insurers, and health maintenance organizations, respectively, and pharmacy benefit managers on behalf of these insurers and health maintenance organizations, from engaging in certain acts against 340B entities for 340B drugs; providing applicability; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; providing an effective date.
AI Summary
This bill creates comprehensive protections for 340B Drug Discount Program entities in Florida, focusing on preventing discriminatory practices by drug manufacturers, health insurance issuers, pharmacy benefit managers, and other third-party payors. The 340B Drug Discount Program is a federal program that allows certain healthcare organizations to purchase prescription drugs at significantly reduced prices. The bill prohibits these entities from engaging in practices that could disadvantage or unfairly treat 340B entities, such as reimbursing them at lower rates than non-340B entities, imposing additional administrative burdens, or interfering with patient choice in obtaining medications. Specifically, the bill restricts actions like imposing unique fees, creating network participation barriers, requiring additional claim documentation, or excluding 340B entities from insurance networks. Any violation of these provisions is considered a deceptive and unfair trade practice under Florida law, potentially subjecting violators to investigative demands, remedies, and penalties. The bill applies to various types of health insurance policies, including individual, group, and health maintenance organization plans, and will take effect on July 1, 2025, aiming to protect healthcare providers and patients participating in the 340B Drug Discount Program.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Died in Health Care Facilities & Systems Subcommittee (on 06/16/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.flsenate.gov/Session/Bill/2025/1527 |
| BillText | https://www.flsenate.gov/Session/Bill/2025/1527/BillText/Filed/PDF |
Loading...